Comparison between Atorvastatin and Rosuvastatin on Secondary Percutaneous Coronary Intervention Rate and the Risk Factors in Patients with Coronary Heart Disease.

Current Drug Metabolism
Jie ZhangJue Li

Abstract

The aim is to compare atorvastatin versus rosuvastatin on secondary percutaneous coronary intervention (PCI) rate and explore risk factors in coronary heart disease (CHD) patients. A cohort study with 283 CHD subjects was launched from 2011 to 2015. Cox proportional hazards regression model, Receiver Operating Characteristic (ROC) and nomogram were used to compare the effect of atorvastatin and rosuvastatin on secondary PCI rate and disease risk factors. Even why the two statins had different effects based on gene expression profile analysis has been explored. Gene FFA (Freely fatty acid), AST (Aspartate Transaminase) and ALT (Alanine transaminase) showed the statistical difference between the four statin groups (P<0.05). In the AA group (Continuous Atorvastatin usage), albumin was a risk factor (Hazard Ratio (HR):1.076, 95%CI (1.001, 1.162), p<0.05). In the AR group (Start with Atorvastatin usage, then change to Rosuvastatin usage), ApoA was a protective factor (HR:0.004, 95%CI (0.001, 0.665), p<0.05). GLB (Galactosidase Beta) was a risk factor (HR:1.262, 95%CI (1.010, 1.576), p<0.05). In RR group (Continuous Rosuvastatin usage), ApoE was a protective factor (HR:0.943, 95%CI (0.890, 1.000), <0.05). ALT was a risk factor (HR:1....Continue Reading

References

Jul 1, 1968·Journal of Atherosclerosis Research·D F Davies, A Clark
May 29, 2007·The American Journal of Cardiology·Prakash C DeedwaniaUNKNOWN IRIS Study Group
Jun 1, 2011·The American Journal of Cardiology·Lutz P BreitlingHermann Brenner
Apr 21, 2012·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Gennaro SardellaFrancesco Fedele
Apr 24, 2012·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Jannet A EindhovenRon T van Domburg
Mar 26, 2013·European Journal of Pharmacology·Masafumi KumazakiAkio Fujimura
Mar 29, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Caroline A SabinJens D Lundgren
Nov 16, 2013·The American Journal of Cardiology·Hisato TakagiUNKNOWN ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
May 2, 2014·Annals of the Royal College of Surgeons of England·J IsherwoodA R Dennison
Jun 1, 2012·Therapeutic Advances in Drug Safety·Miao HuBrian Tomlinson
Aug 16, 2015·Medicinski Glasnik : Official Publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina·Ayşegül KuntAlper Sami Kunt
Aug 28, 2015·Journal of Pharmacology & Pharmacotherapeutics·Sushant KhuranaVarad Gupta
Dec 22, 2015·Spectrochimica Acta. Part A, Molecular and Biomolecular Spectroscopy·Qi WangJie-hua Shi
Aug 4, 2016·Journal of Epidemiology and Community Health·Gilbert MacKenzieJohn Pemberton
Aug 16, 2016·European Heart Journal·Nick TownsendMelanie Nichols
Apr 18, 2017·International Journal of Cardiology·Shih-Chieh ChienJaw-Wen Chen
Mar 24, 2018·International Journal of Molecular Medicine·Ying YuKefang Guo
Nov 18, 2018·Archives of Medical Research·Rosalba C García-MéndezGabriela Borrayo-Sanchez
Dec 7, 2018·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yunan ChangPeng Hu
Mar 11, 2019·The American Journal of Cardiology·Vikas ThondapuIk-Kyung Jang

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.